Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for AMPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 16.50%
March 31, 2026 3.75%
December 31, 2025 13.34%
September 30, 2025 9.04%
June 30, 2025 17.79%
March 31, 2025 14.83%
December 31, 2024 20.35%
September 30, 2024 21.14%
June 30, 2024 20.81%
March 31, 2024 25.13%
December 31, 2023 20.31%
September 30, 2023 27.26%
June 30, 2023 17.93%
March 31, 2023 18.59%
December 31, 2022 25.12%
September 30, 2022 13.21%
June 30, 2022 14.05%
March 31, 2022 20.15%
December 31, 2021 16.35%
September 30, 2021 27.59%
June 30, 2021 8.48%
March 31, 2021 3.84%
December 31, 2020 -6.04%
September 30, 2020 5.74%
June 30, 2020 -1.67%
Date Value
March 31, 2020 4.16%
December 31, 2019 0.91%
September 30, 2019 1.23%
June 30, 2019 59.36%
March 31, 2019 -2.70%
December 31, 2018 1.92%
September 30, 2018 2.14%
June 30, 2018 -4.02%
March 31, 2018 -12.23%
December 31, 2017 1.30%
September 30, 2017 0.30%
June 30, 2017 3.03%
March 31, 2017 1.58%
December 31, 2016 -4.32%
September 30, 2016 6.06%
June 30, 2016 10.13%
March 31, 2016 4.19%
December 31, 2015 9.79%
September 30, 2015 -4.71%
June 30, 2015 -12.34%
March 31, 2015 -1.17%
December 31, 2014 -4.51%
September 30, 2014 -9.01%
June 30, 2014 -2.41%
March 31, 2014 -3.53%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Supernus Pharmaceuticals, Inc. -26.65%
Liquidia Corp. 43.52%
ANI Pharmaceuticals, Inc. 8.65%
Corcept Therapeutics, Inc. 16.45%
Veru, Inc. --